亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis

医学 荟萃分析 肿瘤科 乳腺癌 危险系数 阶段(地层学) 内科学 免疫组织化学 癌症 胃肠病学 妇科 置信区间 生物 古生物学
作者
Yakup Ergün,Gökhan Uçar,Baran Akagündüz
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:115: 102538-102538 被引量:35
标识
DOI:10.1016/j.ctrv.2023.102538
摘要

The prognostic differences between HER2-zero and HER2-low breast cancer (BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between HER2-low and HER2-zero in terms of clinicopathological factors and survival outcomes in early-stage BC.We searched major databases and congress proceedings until November 1, 2022 to identify studies comparing HER2-zero and HER2-low in early-stage BC. HER2-zero immunohistochemically (IHC) was defined as score 0, while HER2-low was defined as IHC 1+ or 2+/in situ hybridization negative.A total of 23 retrospective studies involving 636,535 patients were included. HER2-low rate was 67.5% in the hormone receptor (HR)-positive group, while this rate was 48.6% in the HR-negative group. In the analysis of clinicopathological factors by HR status, the proportion of premenopausal patients within the HR-positive group was greater in the HER2-zero arm (66.5% vs 61.8%), whereas grade 3 tumors (74.2% vs 71.5%), patients younger than 50 years of age (47.3% vs 39.6%), and T3-T4 tumors (7.7% vs 6.3%) within the HR-negative group was higher in the HER2-zero arm. In both the HR-positive and HR-negative groups, the HER2-low arm showed significantly improved results for disease-free survival (DFS) and overall survival (OS). The hazard ratios for DFS and OS in the HR-positive group were 0.88 (95% CI 0.83-0.94) and 0.87 (95% CI 0.78-0.96), respectively. In the HR-negative group, the hazard ratios for DFS and OS were 0.87 (95% CI 0.79-0.97) and 0.86 (95% CI 0.84-0.89), respectively.In early-stage BC, HER2-low is associated with better DFS and OS compared to HER2-zero, regardless of HR status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
starry完成签到 ,获得积分10
8秒前
menyu完成签到,获得积分10
9秒前
科研通AI2S应助图图采纳,获得30
12秒前
黄金枝完成签到 ,获得积分10
15秒前
热心易绿完成签到 ,获得积分10
17秒前
19秒前
28秒前
35秒前
平淡的快乐完成签到,获得积分10
42秒前
充电宝应助平淡的快乐采纳,获得20
47秒前
Sunny完成签到 ,获得积分10
52秒前
李健应助科研通管家采纳,获得10
58秒前
田様应助科研通管家采纳,获得10
58秒前
科研通AI5应助科研通管家采纳,获得10
58秒前
研友_VZG7GZ应助科研通管家采纳,获得10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
科研通AI5应助科研通管家采纳,获得10
59秒前
科研通AI5应助科研通管家采纳,获得10
59秒前
小蘑菇应助科研通管家采纳,获得10
59秒前
科研通AI5应助科研通管家采纳,获得10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
小蘑菇应助科研通管家采纳,获得10
59秒前
科研通AI5应助科研通管家采纳,获得10
59秒前
1234354346完成签到 ,获得积分10
1分钟前
喜之郎果冻完成签到,获得积分10
1分钟前
江姜酱先生完成签到,获得积分10
1分钟前
谦让的西装完成签到 ,获得积分10
1分钟前
扶光完成签到 ,获得积分10
1分钟前
keyanbrant完成签到 ,获得积分10
1分钟前
1分钟前
千寻完成签到,获得积分10
1分钟前
薄荷小新完成签到 ,获得积分10
1分钟前
卡琳完成签到 ,获得积分10
1分钟前
1分钟前
芳芳发布了新的文献求助10
1分钟前
jinmuna完成签到,获得积分10
2分钟前
李健的小迷弟应助芳芳采纳,获得10
2分钟前
科研通AI2S应助头秃科研人采纳,获得10
2分钟前
大模型应助zzz采纳,获得10
2分钟前
cdercder应助头秃科研人采纳,获得20
2分钟前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Ciprofol versus propofol for adult sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysis 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3671207
求助须知:如何正确求助?哪些是违规求助? 3228106
关于积分的说明 9778486
捐赠科研通 2938349
什么是DOI,文献DOI怎么找? 1609872
邀请新用户注册赠送积分活动 760478
科研通“疑难数据库(出版商)”最低求助积分说明 735990